Anthony Francis Yu

Sloan-Kettering Inst Can Research

$2,824,352

Attributed

$2,824,352

Total exposure

Grants

Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $722.7K · FY2017–25

$1M$750K$500K$250K$0

'17

'18

'19

'20

'21

'22

'23

'24

'25

Funding mix

By agency

NIH$2,824,352 · 3

By mechanism

R37$1,767,760 · 1

K23$879,592 · 1

R03$177,000 · 1

Top collaborators

No co-investigators on record.

Most similar at Sloan-Kettering Inst Can Research

Same institution · by research overlap

Craig B Thompson$56,520,903
Robert V Farese$28,829,369
Ross L Levine$31,715,816
Charles L Sawyers$34,701,646
Ottavio Arancio$29,644,569

Others in their field

Other Emerging Leaders on “Chemotherapy”

Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$20,250,477
Olwen Hahn · Brigham And Women'S Hospital$13,557,463
James Dale Berry · Brigham And Women'S Hospital$11,004,714
Jessica Scott · Sloan-Kettering Inst Can Research$7,160,357
Vera Hoffman · Reveal Pharma$6,103,452

Research focus

ChemotherapyCardiovascular SystemWomanCardiotoxicityBreast Cancer TreatmentBreast Cancer TherapyFutureMalignant NeoplasmsMalignant Breast NeoplasmOncologyCancer TherapyGuidelinesMortalityRecommendationEventMorbidity - Disease RateAnthracyclineFrequenciesSafetyCardiovascular Risk FactorLeft Ventricular Ejection FractionInvestigationHeart FailurePrimary Outcome